AC
PBYI icon

Armistice Capital’s Puma Biotechnology PBYI Stock Holding History

Armistice Capital’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-300,000
Closed -$1.27M – 246
2022
Q4 		$1.27M Sell
300,000
-700,000
-70% -$2.42M 0.02% 124
2022
Q3 		$2.37M Sell
1,000,000
-500,000
-33% -$1.46M 0.04% 124
2022
Q2 		$4.28M Buy
+1,500,000
New +$3.73M 0.07% 106

Other funds holding PBYI

CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIM
Hillsdale Investment Management Toronto, Ontario, Canada $4.39B AUM 72.96% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $783M AUM 81.58% 1-Year Est. Return

Armistice Capital's PBYI Position: Q1 2023 in Review

Armistice Capital sold out of Puma Biotechnology (PBYI) in Q1 2023, closing a stake of 300,000 shares — an estimated $1.27M sold.

Armistice Capital first reported a position in PBYI in Q2 2022 and held it in 3 quarters. The position peaked at $4.28M in Q2 2022. 77 funds tracked by Wall St. Rank hold PBYI as of Q1 2023.

  • Armistice Capital reported no remaining Puma Biotechnology position as of Q1 2023 after selling out during the quarter.
  • Armistice Capital sold 300,000 Puma Biotechnology shares in Q1 2023, an estimated $1.27M.
  • Armistice Capital first reported a position in Puma Biotechnology in Q2 2022 and held it in 3 quarters.
  • Armistice Capital's Puma Biotechnology position peaked at $4.28M in Q2 2022.
  • 77 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2023.

Based on Armistice Capital's 13F filing for Q1 2023, filed 15 May 2023.